Bacteriophage therapy: coping with the growing antibiotic resistance problem
Nina Chanishvili A and Rustam Aminov B
+ Author Affiliations
- Author Affiliations
A The Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi 0160, Georgia. Email: nina.chanishvili@gmail.com
B School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom. Email: rustam.aminov@abdn.ac.uk
Microbiology Australia 40(1) 5-7 https://doi.org/10.1071/MA19011
Published: 5 March 2019
Abstract
The global problem of multidrug-resistant bacterial pathogens requires urgent actions, including the development of therapies supplementary or alternative to antibiotics. One of the infection control options could be phage therapy. This article gives a brief overview of phage therapy potentials as well as the challenges it faces in order to become a widely accepted form of infection treatment.
References
[1] Aminov, R. (2017) History of antimicrobial drug discovery: major classes and health impact. Biochem Pharmacol. 133, 4–19.| History of antimicrobial drug discovery: major classes and health impact.Crossref | GoogleScholarGoogle Scholar | 27720719PubMed |
[2] Aminov, R.I. (2010) A brief history of the antibiotic era: lessons learned and challenges for the future. Front. Microbiol. 1, 134.
| A brief history of the antibiotic era: lessons learned and challenges for the future.Crossref | GoogleScholarGoogle Scholar | 21687759PubMed |
[3] Boucher, H.W. et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12.
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.Crossref | GoogleScholarGoogle Scholar | 19035777PubMed |
[4] O’Neill, J. (2014) The review on antimicrobial resistance. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
[5] Aminov, R.I. (2009) The role of antibiotics and antibiotic resistance in nature. Environ. Microbiol. 11, 2970–2988.
| The role of antibiotics and antibiotic resistance in nature.Crossref | GoogleScholarGoogle Scholar | 19601960PubMed |
[6] Davies, J. et al. (2006) The world of subinhibitory antibiotic concentrations. Curr. Opin. Microbiol. 9, 445–453.
| The world of subinhibitory antibiotic concentrations.Crossref | GoogleScholarGoogle Scholar | 16942902PubMed |
[7] Andersson, D.I. and Hughes, D. (2011) Persistence of antibiotic resistance in bacterial populations. FEMS Microbiol. Rev. 35, 901–911.
| Persistence of antibiotic resistance in bacterial populations.Crossref | GoogleScholarGoogle Scholar | 21707669PubMed |
[8] Aminov, R.I. (2011) Horizontal gene exchange in environmental microbiota. Front. Microbiol. 2, 158.
| Horizontal gene exchange in environmental microbiota.Crossref | GoogleScholarGoogle Scholar | 21845185PubMed |
[9] Van Boeckel, T.P. et al. (2014) Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect. Dis. 14, 742–750.
| Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data.Crossref | GoogleScholarGoogle Scholar | 25022435PubMed |
[10] Van Boeckel, T.P. et al. (2015) Global trends in antimicrobial use in food animals. Proc. Natl. Acad. Sci. USA 112, 5649–5654.
| Global trends in antimicrobial use in food animals.Crossref | GoogleScholarGoogle Scholar | 25792457PubMed |
[11] d’Hérelle, F. (1917) Sur un microbe invisible antagoniste des bacilles dysentériques. C. R. Acad. Sci. Ser. D 165, 373–375.
[12] Borysowski, J. and Górski, A. (2008) Is phage therapy acceptable in the immunocompromised host? Int. J. Infect. Dis. 12, 466–471.
| Is phage therapy acceptable in the immunocompromised host?Crossref | GoogleScholarGoogle Scholar | 18400541PubMed |
[13] Międzybrodzki, R. et al. (2012) Clinical aspects of phage therapy. Adv. Virus Res. 83, 73–121.
| Clinical aspects of phage therapy.Crossref | GoogleScholarGoogle Scholar | 22748809PubMed |
[14] McCallin, S. et al. (2013) Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects. Virology 443, 187–196.
| Safety analysis of a Russian phage cocktail: from metagenomic analysis to oral application in healthy human subjects.Crossref | GoogleScholarGoogle Scholar | 23755967PubMed |
[15] Schmelcher, M. et al. (2012) Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 7, 1147–1171.
| Bacteriophage endolysins as novel antimicrobials.Crossref | GoogleScholarGoogle Scholar | 23030422PubMed |
[16] Jalasvuori, M. et al. (2011) Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids. Biol. Lett. 7, 902–905.
| Bacteriophage selection against a plasmid-encoded sex apparatus leads to the loss of antibiotic-resistance plasmids.Crossref | GoogleScholarGoogle Scholar | 21632619PubMed |
[17] Zhang, Q.G. and Buckling, A. (2012) Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms. Evol. Appl. 5, 575–582.
| Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms.Crossref | GoogleScholarGoogle Scholar | 23028398PubMed |
[18] O’Sullivan, L. et al. (2016) Bacteriophage-based tools: recent advances and novel applications. F1000Res. 5, 2782.
| Bacteriophage-based tools: recent advances and novel applications.Crossref | GoogleScholarGoogle Scholar | 27990274PubMed |
[19] Torres-Barceló, C. and Hochberg, M.E. (2016) Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 24, 249–256.
| Evolutionary rationale for phages as complements of antibiotics.Crossref | GoogleScholarGoogle Scholar | 26786863PubMed |
[20] Kazi, M. and Annapure, U.S. (2016) Bacteriophage biocontrol of foodborne pathogens. J. Food Sci. Technol. 53, 1355–1362.
| Bacteriophage biocontrol of foodborne pathogens.Crossref | GoogleScholarGoogle Scholar | 27570260PubMed |
[21] Lerminiaux, N.A. and Cameron, A.D.S. (2019) Horizontal transfer of antibiotic resistance genes in clinical environments. Can. J. Microbiol. 65, 34–44.
| Horizontal transfer of antibiotic resistance genes in clinical environments.Crossref | GoogleScholarGoogle Scholar | 30248271PubMed |
[22] Sybesma, W. et al. (2018) Silk route to the acceptance and re-implementation of bacteriophage therapy—part II. Antibiotics (Basel) 7, 1–23.
| Silk route to the acceptance and re-implementation of bacteriophage therapy—part II.Crossref | GoogleScholarGoogle Scholar |
[23] Jault, P. et al. (2019) Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 19, 35–45.
| Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial.Crossref | GoogleScholarGoogle Scholar | 30292481PubMed |
[24] Leitner, L. et al. (2017) Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 17, 90.
| Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial.Crossref | GoogleScholarGoogle Scholar | 28950849PubMed |
[25] Ujmajuridze, A. et al. (2018) Adapted bacteriophages for treating urinary tract infections. Front. Microbiol. 9, 1832.
| Adapted bacteriophages for treating urinary tract infections.Crossref | GoogleScholarGoogle Scholar | 30131795PubMed |
